




Searching News Database: AGGRASTAT
HSMN NewsFeed - 16 Mar 2020
ADVANZ PHARMA Corp. Limited to Acquire Specialty Pharmaceutical Company Correvio Pharma Corp.
ADVANZ PHARMA Corp. Limited to Acquire Specialty Pharmaceutical Company Correvio Pharma Corp.
HSMN NewsFeed - 24 Dec 2019
Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events
Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events
HSMN NewsFeed - 11 Dec 2019
Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value
Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value
HSMN NewsFeed - 25 Jul 2019
U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant)
U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant)
HSMN NewsFeed - 2 Jan 2019
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
HSMN NewsFeed - 17 May 2018
Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess(R) in China
Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess(R) in China
HSMN NewsFeed - 17 Apr 2018
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess(R)
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess(R)
HSMN NewsFeed - 12 Dec 2017
Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
HSMN NewsFeed - 12 Jun 2017
Cardiome Announces Commercial Launch of BRINAVESS(R) (Vernakalant Hydrochloride) in Canada
Cardiome Announces Commercial Launch of BRINAVESS(R) (Vernakalant Hydrochloride) in Canada
HSMN NewsFeed - 3 Mar 2017
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in France
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in France
HSMN NewsFeed - 8 Dec 2016
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK
HSMN NewsFeed - 12 May 2016
Cardiome Announces the Launch of ESMOCARD Solution for Injection in France
Cardiome Announces the Launch of ESMOCARD Solution for Injection in France
HSMN NewsFeed - 25 Jul 2011
Medicure Announces Appointment of Dawson Reimer as President and Chief Operating Officer
Medicure Announces Appointment of Dawson Reimer as President and Chief Operating Officer
HSMN NewsFeed - 30 Jan 2008
Iroko Pharmaceuticals Acquires Rights to Cardiovascular Product from Merck & Co., Inc.
Iroko Pharmaceuticals Acquires Rights to Cardiovascular Product from Merck & Co., Inc.
HSMN NewsFeed - 20 Sep 2007
Medicure Announces Completion of Enrollment in Pivotal Phase 3 MEND-CABG II Trial
Medicure Announces Completion of Enrollment in Pivotal Phase 3 MEND-CABG II Trial
HSMN NewsFeed - 27 Jul 2007
Positive Aggrastat(R) Results Versus Integrilin(R) Featured in American Heart Journal
Positive Aggrastat(R) Results Versus Integrilin(R) Featured in American Heart Journal
HSMN NewsFeed - 12 Dec 2006
Medicure Announces Special Protocol Assessment With the FDA For Phase III MEND-CABG II Study
Medicure Announces Special Protocol Assessment With the FDA For Phase III MEND-CABG II Study
HSMN NewsFeed - 14 Nov 2006
Medicure Announces New AGGRASTAT(R) Data at 2006 Scientific Sessions of the American Heart Association
Medicure Announces New AGGRASTAT(R) Data at 2006 Scientific Sessions of the American Heart Association
HSMN NewsFeed - 16 Aug 2006
Medicure Announces Clinical Agreement with Duke and Montreal Heart Institute on Phase III MC-1 Study
Medicure Announces Clinical Agreement with Duke and Montreal Heart Institute on Phase III MC-1 Study
Additional items found! 31

Members Archive contains
31 additional stories matching:
AGGRASTAT
(Password required)
AGGRASTAT
(Password required)